Charter Research & Investment Group Inc. Has $5.90 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Charter Research & Investment Group Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,234 shares of the company’s stock after buying an additional 107 shares during the quarter. Johnson & Johnson accounts for about 5.4% of Charter Research & Investment Group Inc.’s investment portfolio, making the stock its 2nd largest position. Charter Research & Investment Group Inc.’s holdings in Johnson & Johnson were worth $5,899,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also modified their holdings of the company. RE Dickinson Investment Advisors LLC lifted its position in shares of Johnson & Johnson by 163.3% during the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after buying an additional 98 shares during the period. Morton Brown Family Wealth LLC raised its position in Johnson & Johnson by 78.0% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after purchasing an additional 78 shares during the last quarter. Advanced Research Investment Solutions LLC raised its position in Johnson & Johnson by 200.0% in the 1st quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after purchasing an additional 120 shares during the last quarter. Professional Financial Advisors LLC raised its position in Johnson & Johnson by 47.9% in the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after purchasing an additional 68 shares during the last quarter. Finally, Goodman Advisory Group LLC bought a new position in Johnson & Johnson in the 2nd quarter valued at $39,000. Institutional investors own 68.59% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,410 shares of the stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total value of $2,845,822.20. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,366,753.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Johnson & Johnson news, VP Peter Fasolo sold 22,864 shares of the stock in a transaction dated Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the completion of the sale, the vice president now directly owns 114,676 shares in the company, valued at $18,864,202. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kathryn E. Wengel sold 16,410 shares of the stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total value of $2,845,822.20. Following the completion of the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,366,753.62. The disclosure for this sale can be found here. Insiders sold 118,795 shares of company stock worth $20,230,174 over the last ninety days. 0.35% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have issued reports on JNJ. Bank of America cut their price objective on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Atlantic Securities cut their price objective on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Raymond James cut their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Morgan Stanley lowered their target price on Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 19th. Finally, Credit Suisse Group initiated coverage on Johnson & Johnson in a research note on Thursday. They issued a “neutral” rating and a $170.00 target price for the company. Seven analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $181.33.

Johnson & Johnson Trading Up 0.8 %

NYSE JNJ opened at $176.20 on Friday. The stock has a 50-day simple moving average of $167.84 and a 200 day simple moving average of $171.40. The company has a market capitalization of $460.67 billion, a PE ratio of 24.54, a P/E/G ratio of 3.44 and a beta of 0.57. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. The business had revenue of $23.79 billion during the quarter, compared to the consensus estimate of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.60 earnings per share. Research analysts forecast that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson announced that its Board of Directors has initiated a stock repurchase program on Wednesday, September 14th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the company to purchase up to 1.2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be issued a $1.13 dividend. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 dividend on an annualized basis and a yield of 2.57%. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.